{"nct_id":"NCT02564263","title":"Study of Pembrolizumab (MK-3475) Versus Investigator's Choice Standard Therapy for Participants With Advanced Esophageal/ Esophagogastric Junction Carcinoma That Progressed After First-Line Therapy (MK-3475-181/KEYNOTE-181)","status":"COMPLETED","status_verified_date":"2023-02","start_date":"2015-12-01","start_date_type":"ACTUAL","primary_completion_date":"2018-10-15","primary_completion_date_type":"ACTUAL","completion_date":"2022-03-14","completion_date_type":"ACTUAL","phases":["PHASE3"],"tickers":["MRK"]}